ResearcherEmory UniversityActive in the last 2 years
Chrystal M Paulos
Matched on ORCID iD 0000-0002-0784-2601; OpenAlex author ID A5044271217; NIH RePORTER profile ID 9401019. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 2
- Labs led
- 2
- Collaborators
- 20
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 grant · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers, 1 grant
Papers 5
- A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling. Co-author DOI 10.1016/j.canlet.2025.218233↗
- High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-25-1697↗
- Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. Co-author DOI 10.1136/jitc-2023-008086↗
- Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy. Co-author DOI 10.4081/oncol.2019.430↗
- Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Co-author DOI 10.1186/s13045-017-0459-2↗
Grants 2
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gregory B. Lesinski · 3 shared papers, 1 shared grant, 2024–2026 · strength 1.67
- Grant Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer R01CA287866↗
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Edmund K Waller · 1 shared grant, 2026 · strength 1.00
- Cameron J. Herting · 3 shared papers, 2024–2026 · strength 0.67
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Paper Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. DOI 10.1136/jitc-2023-008086↗
- Natalie K. Horvat · 3 shared papers, 2024–2026 · strength 0.67
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Paper Clinically relevant orthotopic pancreatic cancer models for adoptive T cell transfer therapy. DOI 10.1136/jitc-2023-008086↗
- Emily R. Greene · 2 shared papers, 2026 · strength 0.47
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Olatunji Boladale Alese · 2 shared papers, 2026 · strength 0.47
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Maria Diab · 2 shared papers, 2026 · strength 0.47
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Bassel F. El‐Rayes · 2 shared papers, 2026 · strength 0.47
- Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
- Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
- Olumide B. Gbolahan · 1 shared paper, 2026 · strength 0.24
- Juan Manuel Sarmiento · 1 shared paper, 2026 · strength 0.23
- Alyssa M. Krasinskas · 1 shared paper, 2026 · strength 0.23
- Mihir Maheshkumar Shah · 1 shared paper, 2026 · strength 0.23
- Shishir Kumar Maithel · 1 shared paper, 2026 · strength 0.23
- Richard A. Moffitt · 1 shared paper, 2024 · strength 0.20
- Mark P. Rubinstein · 2 shared papers, 2017–2019 · strength 0.18
- Paper Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immu… DOI 10.4081/oncol.2019.430↗
- Paper Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. DOI 10.1186/s13045-017-0459-2↗
- Ernest Ramsay Camp · 1 shared paper, 2019 · strength 0.12
- Jacob S. Bowers · 1 shared paper, 2019 · strength 0.12
- David J. Cole · 1 shared paper, 2017 · strength 0.06
- Shikhar Mehrotra · 1 shared paper, 2017 · strength 0.06
- Carolyn D. Britten · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.